HIV drugs make the virus easy to control, but pharmaceutical companies continue to seek vaccines that can provide people with preventive measures.One such effort by Johnson & Johnson has Can’t reach In a mid-term clinical trial to test the vaccine in young heterosexual women in Southern Africa.
Johnson & Johnson said on Tuesday that preliminary analysis of the Phase 2b study showed that the vaccine did not provide enough protection to prevent HIV infection. Based on these results, clinical trials will not continue.
The Johnson & Johnson HIV vaccine is based on a “mosaic” of immunogens that are designed to induce an immune response against a series of HIV strains found around the world.It is made using the proprietary AdVac technology of the pharmaceutical giant, which is the foundation of the company FDA approved Ebola vaccine with Covid-19 lens with emergency use authorization. Like those vaccines, the HIV vaccine uses an adenovirus strain, a virus that causes the common cold, and is carefully designed to not cause infection. The virus delivers four mosaic antigens to cells designed to trigger an immune response.
Clinical trials in sub-Saharan Africa are funded by the Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases. The study began in 2017 and recruited about 2,600 young women in Malawi, Mozambique, South Africa, Zambia and Zimbabwe-the region is a region of the African continent. It is estimated that last year women and girls in this region accounted for all new 63% of people infected with HIV.United Nations Joint Programme UNAIDS.
Participants in the trial were vaccinated four times in a year. In the third and fourth vaccination, the vaccine contains an adjuvant, which is a component that enhances the immune response. A preliminary analysis was conducted one year after the last shooting. Johnson & Johnson said that the analysis showed that the vaccine is effective at 25.2% in preventing infection. Women infected with HIV are directed to medical institutions for treatment.
The results are in stark contrast to the powerful efficacy demonstrated in preclinical studies conducted in monkeys. The Johnson & Johnson vaccine against the ape version of HIV reduces the risk of infection by 94%. result Report in 2017. But the results of Phase 2b provide another example of human testing failing to reproduce the encouraging data from animal studies. In a prepared statement, Paul Stoffels, chief scientific officer of Johnson & Johnson, said that HIV has long posed challenges to vaccine research because of its ability to attack, hijack, and evade the human immune system.
Johnson & Johnson vaccine is safe and well tolerated by patients, and no serious adverse events have been reported.This is an encouraging sign for another J&J HIV experimental vaccine candidate Different ingredientsThe vaccine is currently being evaluated among men who have sex with men and transgender people. Like the vaccine evaluated in the African study, the vaccine also consists of four immunogens, but reflects the different strains circulating in the Americas and Europe where the key research is being conducted. Johnson & Johnson said that in view of these differences, the Independent Data Security Monitoring Committee decided to continue the third phase of the study.According to the National Institutes of Health, which provides funding for clinical research, the research is expected Completed in 2024.
Images of Flickr users Agency for International Development Through knowledge sharing license
